Trial Profile

A Phase I Clinical Trial of Eyecyte-RPE for the Treatment of Dry Age-related Macular Degeneration (Dry AMD)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Feb 2020 According to an Eyestem media release, the company announced the completion of a pre-IND (Investigational New Drug) meeting with the FDA regarding regulatory roadmaps for its flagship product Eyecyte-RPE and obtain encouraging feedback from the FDA. IND application is expected to file this year and the company plans to commence the clinical trials by next year.
02 Aug 2019 New trial record
01 Jul 2019 According to an Eyestem media release, the recent funding will help the company to complete all the pre-clinical work to file for an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) and be ready for this phase one clinical trial by end of next year (18 months).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com